External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home ERA 2025
Roche and Genentech at

ERA 2025

June 04 - June 07
Vienna, Austria / Virtual (Hybrid)
era-online.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
07:45 AM
Duration 90mins Vienna, Austria
Effects of obinutuzumab on urinary biomarkers in lupus nephritis: a post hoc exploratory analysis of the Phase II NOBILITY study
Mejia-Vilet JM, Clarke HJ, Lanza B, Anania V, Pendergraft III WF, Omachi TA, Parodis I, Jones R, Lightstone L, Rovin BH, Raghu H
Immunology - Nephrology - Rheumatology | Lupus nephritis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 91mins Vienna, Austria
INShore: Phase III, multicentre, randomised, open-label study of efficacy and safety of obinutuzumab vs MMF in patients with childhood-onset idiopathic nephrotic syndrome
Hogan J, Ding J, Greenbaum L, Mizerska-Wasiak M, Nozu K, Watanabe A, Boston H, Chen DC, Lanza B, Lehane P
Immunology - Nephrology | Childhood-onset idiopathic nephrotic syndrome

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins Vienna, Austria
Patient-reported fatigue is improved or maintained over 2 years in patients receiving crovalimab▼ for paroxysmal nocturnal haemoglobinuria (PNH)
H. STAUNTON, J. STEFANI, P. LEON
Haematology | Paroxysmal Nocturnal Hemoglobinuria

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:45 AM
Duration 92mins Vienna, Austria
Low rate of infusion-related reactions and high treatment adherence with obinutuzumab in patients with active lupus nephritis: analysis of the NOBILITY and REGENCY studies
Jones R, Rovin BH, Sehgal H, Kirchner P, Yoo B, Hassan I, Schindler T, Martins E, Pendergraft W, Garg JP, Vital EM, Lightstone L
Immunology - Nephrology - Rheumatology | Lupus nephritis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:00 PM
Duration 90mins Vienna, Austria
Suppression of complement alternative pathway by monthly dosing of sefaxersen, a novel antisense oligonucleotide therapy in development for IgAN
Jeannette Lo, Nelson Guerreiro, Nadine Schmit, Lixuan Yin, Terry Barrett, Ji Cheng, Vishal Duggal, Gary Brice
Nephrology | IgA nephropathy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.